Here are some strategies to consider for optimal utilization.
Infectious disease clinicians face an escalating challenge: multidrug-resistant (MDR) infections that render traditional antimicrobial treatments ineffective. The emergence of MDR pathogens such as carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA) is outpacing the development of new antibiotics.1 Antimicrobial stewardship (AMS) is no longer just an initiative—it’s a necessity.
AMS programs aim to optimize antimicrobial use, ensuring the best patient outcomes while slowing resistance. But stewardship isn’t just about restricting antibiotics—it’s about precision, surveillance, and education. Additionally, as healthcare institutions navigate antimicrobial stewardship efforts, they must also balance operational efficiency, including
Multidrug resistance is particularly concerning in gram-negative bacteria, which have evolved complex defense mechanisms, including efflux pumps and enzyme production that deactivate antibiotics.2 A prime example is Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria.
Rapid diagnostics such as polymerase chain reaction (PCR) and matrix-assisted laser desorption/ionization (MALDI-TOF) mass spectrometry can identify resistant strains faster than traditional cultures.3 Yet, accessibility remains a barrier. Investing in rapid diagnostics is not optional; it’s imperative.
AMS programs are essential for curbing unnecessary antibiotic use, but they must evolve beyond restriction policies to provide clinicians with actionable guidance.4
A significant challenge is empiric therapy—how do we balance early, aggressive treatment with antimicrobial stewardship principles? Overuse of broad-spectrum agents like piperacillin-tazobactam and meropenem contributes to resistance, yet under-treating sepsis risks mortality.5
A strategy gaining traction is “diagnostic-driven de-escalation.”6 By leveraging biomarkers and microbial surveillance, we can personalize therapy instead of relying on a one-size-fits-all approach.
Pharmacokinetics and pharmacodynamics (PK/PD) are underutilized in AMS but can be game-changers in optimizing dosing regimens.7 Extended and continuous infusions of beta-lactams, for example, improve time-dependent killing while reducing toxicity.
Rather than just focusing on which antibiotic to use, how it is administered is just as critical.
The success of an ASP hinges not just on guidelines but on clinician engagement. While data-driven restrictions are necessary, AMS teams must shift from being "the antibiotic police" to trusted collaborators.4
At a Boston teaching hospital, a stewardship team embedded real-time consultation within the EMR system, offering personalized recommendations rather than blanket restrictions. The result? A 22% reduction in broad-spectrum antibiotic use without negatively impacting outcomes.8
Stewardship works best when it’s integrated into clinical workflow rather than imposed as an external control.
One of the most underutilized AMS strategies is predictive resistance mapping.9 By analyzing hospital antibiograms alongside regional resistance data, we can anticipate trends before they escalate.
At a Midwestern academic center, researchers developed a machine-learning model that predicts resistance patterns based on patient demographics and prior antibiotic exposure.9 Their findings? Certain hospital units were unknowingly driving resistance cycles due to persistent empiric overuse of fluoroquinolones.
Surveillance isn’t just about tracking resistance—it’s about preventing its emergence.
The biggest barrier to AMS isn’t just lack of resources—it’s clinician mindset. Many physicians were trained in an era where more antibiotics meant better care.4
Changing this culture requires tailored education. Instead of generic lectures, AMS teams at a California hospital introduced case-based learning sessions, where physicians discussed real patient scenarios and debated antibiotic choices.
Despite AMS efforts, resistance will continue unless we explore alternative therapies.7
Exciting developments include:
Yet, challenges remain. Will regulatory bodies fast-track approval for these alternatives? Will hospitals invest in AMS when short-term costs seem high? Healthcare institutions must balance antimicrobial stewardship with broader financial and operational priorities, including healthcare revenue cycle management, to sustain these long-term innovations.
AMS is no longer just about antibiotic restrictions—it’s about precision, collaboration, and forward-thinking strategies. Infectious disease clinicians play a pivotal role in shaping the future of antimicrobial use.
To fight multidrug resistance, we need to refine how we diagnose, prescribe, and educate. The future of infectious disease management isn’t just about new antibiotics—it’s about using the ones we have, smarter.
